We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
McKesson (MCK) Stock Drops Despite Market Gains: Important Facts to Note
Read MoreHide Full Article
McKesson (MCK - Free Report) closed the most recent trading day at $660.86, moving -0.05% from the previous trading session. This change lagged the S&P 500's daily gain of 1.77%. Elsewhere, the Dow saw an upswing of 1.42%, while the tech-heavy Nasdaq appreciated by 2.28%.
Coming into today, shares of the prescription drug distributor had gained 10.62% in the past month. In that same time, the Medical sector lost 1.17%, while the S&P 500 lost 5.73%.
The investment community will be paying close attention to the earnings performance of McKesson in its upcoming release. The company is forecasted to report an EPS of $9.81, showcasing a 58.74% upward movement from the corresponding quarter of the prior year. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $93.09 billion, up 21.92% from the year-ago period.
MCK's full-year Zacks Consensus Estimates are calling for earnings of $32.76 per share and revenue of $360.63 billion. These results would represent year-over-year changes of +19.39% and +16.73%, respectively.
Investors should also pay attention to any latest changes in analyst estimates for McKesson. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 0.04% lower. McKesson presently features a Zacks Rank of #3 (Hold).
In terms of valuation, McKesson is currently trading at a Forward P/E ratio of 20.18. This represents a premium compared to its industry's average Forward P/E of 16.74.
Also, we should mention that MCK has a PEG ratio of 1.41. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. The Medical - Dental Supplies was holding an average PEG ratio of 1.78 at yesterday's closing price.
The Medical - Dental Supplies industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 82, which puts it in the top 33% of all 250+ industries.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
McKesson (MCK) Stock Drops Despite Market Gains: Important Facts to Note
McKesson (MCK - Free Report) closed the most recent trading day at $660.86, moving -0.05% from the previous trading session. This change lagged the S&P 500's daily gain of 1.77%. Elsewhere, the Dow saw an upswing of 1.42%, while the tech-heavy Nasdaq appreciated by 2.28%.
Coming into today, shares of the prescription drug distributor had gained 10.62% in the past month. In that same time, the Medical sector lost 1.17%, while the S&P 500 lost 5.73%.
The investment community will be paying close attention to the earnings performance of McKesson in its upcoming release. The company is forecasted to report an EPS of $9.81, showcasing a 58.74% upward movement from the corresponding quarter of the prior year. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $93.09 billion, up 21.92% from the year-ago period.
MCK's full-year Zacks Consensus Estimates are calling for earnings of $32.76 per share and revenue of $360.63 billion. These results would represent year-over-year changes of +19.39% and +16.73%, respectively.
Investors should also pay attention to any latest changes in analyst estimates for McKesson. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 0.04% lower. McKesson presently features a Zacks Rank of #3 (Hold).
In terms of valuation, McKesson is currently trading at a Forward P/E ratio of 20.18. This represents a premium compared to its industry's average Forward P/E of 16.74.
Also, we should mention that MCK has a PEG ratio of 1.41. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. The Medical - Dental Supplies was holding an average PEG ratio of 1.78 at yesterday's closing price.
The Medical - Dental Supplies industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 82, which puts it in the top 33% of all 250+ industries.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.